Skip to main content

Table 1 Impact of NEFM on overall survival (OS) in Pan-cancer RNA-seq in Kaplan–Meier plotter

From: NEFM DNA methylation correlates with immune infiltration and survival in breast cancer

Cancers No. of patients MST (OS,Month) HR p
NEFM high expression NEFM low expression
Kidney renal clear cell carcinoma 530 36.57 52.23 1.49 0.031
Lung adenocarcinoma 501 40.3 54.4 1.55 0.0046
Stomach adenocarcinoma 371 25.97 56.2 1.5 0.025
Bladder carcinoma 405 31.37 42.33 1.35 0.047
Head–neck squamous cell carcinoma 499 37.8 66.73 1.43 0.012
Ovarian cancer 373 43.8 45.47 1.37 0.027
Sarcoma 259 36.27 82.13 1.96 0.0011
Pancreatic ductal adenocarcinoma 177 22.03 15.57 0.57 0.011
Cervical squamous cell carcinoma 304 29.3 68.4 1.52 0.13
Lung squamous cell carcinoma 495 44.87 71.1 1.33 0.059
Rectum adenocarcinoma 502, NA NA 3.17 0.098
Thyroid carcinoma 502 NA NA 0.36 0.053
Pheochromocytoma and paraganglioma 178 NA NA 0.18 0.035
Uterine corpus endometrial carcinoma 543 103.73 51.6 0.7 0.097
  1. Significant p value < 0.05 is in bold